Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Nutriband Inc (NTRB)

Nutriband Inc (NTRB)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Nutriband Receives Notice Of Allowance For New U.S. Patent Covering Its Transdermal Abuse Deterrent Technology Aversaâ„¢

NTRB : 7.81 (+17.09%)
NTRBW : 2.25 (+27.12%)
Nutriband Issues Letter to Shareholders

NTRB : 7.81 (+17.09%)
NTRBW : 2.25 (+27.12%)
Nutriband Extends Chinese Patent to Macao for its AVERSAâ„¢ Abuse Deterrent Transdermal Technology

NTRB : 7.81 (+17.09%)
NTRBW : 2.25 (+27.12%)
Nutriband Inc. Reports Record Third Quarter Revenue and Advances AVERSAâ„¢ Fentanyl Development Plans

Nutriband Inc. reports record Q3 revenue and advances AVERSA Fentanyl development, targeting NDA submission in 2025.Quiver AI SummaryNutriband Inc. announced its third-quarter financial results for 2024,...

NTRB : 7.81 (+17.09%)
Nutriband Inc. Quarterly Report Highlights Record Revenue for Q3 up 50.94% YOY and Strategic Progress Toward NDA Filing for AVERSA Fentanyl in 2025

NTRB : 7.81 (+17.09%)
NTRBW : 2.25 (+27.12%)
Nutriband Inc. to Present at The 2024 Noble Conference in Boca Raton on December 4th

NTRB : 7.81 (+17.09%)
NTRBW : 2.25 (+27.12%)
Nutriband Receives Hong Kong Patent Notice of Publication for Its Aversaâ„¢ Abuse Deterrent Transdermal Technology

NTRB : 7.81 (+17.09%)
NTRBW : 2.25 (+27.12%)
As Fentanyl Crisis Escalates, Abuse-Deterrent Formulations to Zero in on the Rising Epidemic of Opiate Abuse

EQNX::TICKER_START (NASDAQ:NTRB),(NASDAQ:NTRBW),(NYSE:TEVA),(NYSE:LLY),(NYSE:NVS),(NASDAQ:AMRX) EQNX::TICKER_END

NTRB : 7.81 (+17.09%)
NTRBW : 2.25 (+27.12%)
LLY : 878.31 (+0.91%)
NVS : 106.26 (-0.67%)
TEVA : 16.83 (-2.66%)
AMRX : 7.85 (-1.51%)
As Fentanyl Crisis Escalates, Abuse-Deterrent Formulations to Zero in on the Rising Epidemic of Opiate Abuse

NTRB : 7.81 (+17.09%)
NTRBW : 2.25 (+27.12%)
LLY : 878.31 (+0.91%)
NVS : 106.26 (-0.67%)
TEVA : 16.83 (-2.66%)
AMRX : 7.85 (-1.51%)
NUTRIBAND RECEIVES CHINA PATENT NOTICE OF ALLOWANCE FOR ITS AVERSAâ„¢ ABUSE DETERRENT TRANSDERMAL TECHNOLOGY

Notice of Allowance received from Chinese National Intellectual Property Administration (CNIPA) for a patent application covering its Nutriband AVERSA™ abuse deterrent transdermal technology   Nutriband...

NTRB : 7.81 (+17.09%)
NTRBW : 2.25 (+27.12%)

Barchart Exclusives

3 High-Yielding Dividend Kings to Buy to Hand Over Fist
Dividend Kings, with 50+ years of growth, offer stability. Here are three top-rated, high-yield picks. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar